CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance at Sep. 30, 2017	$ 380,823	$ 482	$ 916,726	$ (461,867)	$ (74,518)
Beginning balance, Shares at Sep. 30, 2017		304,440
Issuance of common stock in public offering, net of issuance costs	297,932	$ 44	297,888
Issuance of common stock in public offering, net of issuance costs, Shares		33,120
Issuance of common stock from exercise of stock options	620	$ 4	616
Issuance of common stock from exercise of stock options, Shares		2,687
Net loss	(295,167)			(295,167)
Stock-based compensation	31,627		31,627
Other comprehensive income (loss)	(676)				(676)
Ending balance at Sep. 30, 2018	415,159	$ 530	1,246,857	(757,034)	(75,194)
Ending balance, Shares at Sep. 30, 2018		340,247
Issuance of common stock in public offering, net of issuance costs	324,638	$ 34	324,604
Issuance of common stock in public offering, net of issuance costs, Shares		26,220
Issuance of common stock from exercise of stock options, Shares		150
Net loss	(71,906)			(71,906)
Stock-based compensation	9,683		9,683
Other comprehensive income (loss)	(3,494)				(3,494)
Ending balance at Dec. 31, 2018	674,080	$ 564	1,581,144	(828,940)	(78,688)
Ending balance, Shares at Dec. 31, 2018		366,617
Issuance of common stock from exercise of stock options	2,878	$ 6	2,872
Issuance of common stock from exercise of stock options, Shares		4,452
Net loss	(9,019)			(9,019)
Stock-based compensation	48,030		48,030
Other comprehensive income (loss)	10,065				10,065
Ending balance at Dec. 31, 2019	726,034	$ 570	1,632,046	(837,959)	(68,623)
Ending balance, Shares at Dec. 31, 2019		371,069
Issuance of common stock from exercise of stock options	1,579	$ 7	1,572
Issuance of common stock from exercise of stock options, Shares		4,127
Net loss	(58,128)			(58,128)
Common stock withheld for employee tax obligations	(1,826)		(1,826)
Stock-based compensation	58,359		58,359
Other comprehensive income (loss)	15,072				15,072
Ending balance at Dec. 31, 2020	$ 741,090	$ 577	$ 1,690,151	$ (896,087)	$ (53,551)
Ending balance, Shares at Dec. 31, 2020		375,196

GW PHARMACEUTICALS PLC 10-K